Gentisic acid

Research use only, not for human use.

Gentisic acid is a dihydroxybenzoic acid.

Gentisic acid is a dihydroxybenzoic acid. It is a derivative of benzoic acid and a minor (1%) product of the metabolic break down of aspirin, excreted by the kidneys. It is also found in the African tree Alchornea cordifolia and in wine.(In Vitro):2,5-Dihydroxybenzoic acid (Gentisic acid) is a derivative of benzoic and a minor product of the metabolic break down of aspirin. 2,5-Dihydroxybenzoic acid is also a component of many traditional liquors and herbal remedies, is singled out as a powerful inhibitor of fibroblast growth factors. 2,5-Dihydroxybenzoic acid is used as a lead to identify additional compounds with better inhibitory characteristics generating a new chemical class of fibroblast growth factor inhibitors that includes the agent responsible for alkaptonuria. Through low and high resolution approaches, using representative members of the fibroblast growth factor family and their cell receptors, it is shown that this class of inhibitors may employ two different mechanisms to interfere with the assembly of the signaling complexes that trigger fibroblast growth factor-driven mitogenesis.(In Vivo):It is verified from in vivo disease models that this group of inhibitors (e.g., 2,5-Dihydroxybenzoic acid) may be of interest to treat cancer and angiogenesis-dependent diseases.

2,5-Dihydroxybenzoic acid (Gentisic acid) is a derivative of benzoic and a minor product of the metabolic break down of aspirin. 2,5-Dihydroxybenzoic acid is also a component of many traditional liquors and herbal remedies, is singled out as a powerful inhibitor of fibroblast growth factors. 2,5-Dihydroxybenzoic acid is used as a lead to identify additional compounds with better inhibitory characteristics generating a new chemical class of fibroblast growth factor inhibitors that includes the agent responsible for alkaptonuria. Through low and high resolution approaches, using representative members of the fibroblast growth factor family and their cell receptors, it is shown that this class of inhibitors may employ two different mechanisms to interfere with the assembly of the signaling complexes that trigger fibroblast growth factor-driven mitogenesis.

It is verified from in vivo disease models that this group of inhibitors (e.g., 2,5-Dihydroxybenzoic acid) may be of interest to treat cancer and angiogenesis-dependent diseases.

Gentisic acid | NSC 27224 | NSC-27224

GPCR/G Protein

Antibacterial

Others

Others-Field

——

490-79-9

154.12

C7H6O4

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 648.85 mM

c1cc(c(cc1O)C(=O)O)O

Benzoic acid, 2,5-dihydroxy-

(-20℃)

With Ice Pack

≥ 2 years